{"id":40655,"date":"2026-03-29T00:26:08","date_gmt":"2026-03-29T00:26:08","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/40655\/"},"modified":"2026-03-29T00:26:08","modified_gmt":"2026-03-29T00:26:08","slug":"ubs-reduces-stake-in-biotech-firm-abivax-below-reporting-threshold","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/40655\/","title":{"rendered":"UBS Reduces Stake in Biotech Firm Abivax Below Reporting Threshold"},"content":{"rendered":"


\n\t
\n\t\tUBS<\/a>, Reduces<\/a>\t\t
\n\t\t29.03.2026 – 00:37:34 | boerse-global.de
\n\t <\/p>\n

UBS Group reduces its holding in Abivax below a key threshold, as the biotech firm updates its capital structure and shares decline nearly 6%.<\/p>\n


\n
\n\t
\n <\/p>\n

\t\t\t\t\t\t\t\t\t\t\t <\/p>\n

\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t \"UBS <\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t UBS Reduces Stake in Biotech Firm Abivax Below Reporting Threshold – Foto: \u00fcber boerse-global.de\t\t\t\t\t <\/p>\n

\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t<\/a><\/p>\n

\t\t\t\t
\n
\n
\n
\n
\n\t
\n
\n\t
\n
\n\t
\n
\n\t
\n\t <\/p>\n

A significant shift has occurred among the major shareholders of Abivax. The Swiss banking group UBS Group has scaled back its investment in the biotechnology company, crossing below a key regulatory threshold. This move coincides with a period of recent weakness for the company’s shares on the exchange.<\/p>\n

A Shift in Shareholder Dynamics<\/p>\n

According to recent filings with the French Financial Markets Authority (AMF), UBS Group’s holding fell below the 5% mark for both capital and voting rights on March 24, 2026. The reduction resulted from an off-market sale of shares.<\/p>\n

Following this transaction, UBS indirectly holds 3,227,593 shares. This position equates to 4.11% of the share capital and 3.99% of the exercisable voting rights. When a major institutional investor trims its position, it often draws heightened market attention to the short-term supply of shares.<\/p>\n

Should investors sell immediately? Or is it worth buying Abivax?<\/a><\/p>\n

Updated Capital Structure Details<\/p>\n

In conjunction with this shareholder change, Abivax has published current details of its capital structure. As of the reference date of February 28, 2026, the company’s share capital comprised the following:<\/p>\n

Share Capital: 79,185,160 shares
\nTheoretical Voting Rights: 81,538,485
\nExercisable Voting Rights: 81,538,485
\nCapital Value: \u20ac792,028.88<\/p>\n

This disclosure provides a fresh basis for evaluating the company. The stock closed trading on March 27 at \u20ac89.20, marking a decline of nearly 6%. The stake reduction by UBS, combined with the newly confirmed capital data, sets a new context for share price discovery in the coming weeks at the current level of approximately \u20ac89.<\/p>\n

Ad<\/p>\n

Abivax Stock: New Analysis – 29 March<\/p>\n

Fresh Abivax information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Abivax analysis…<\/a><\/p>\n

\t
\n
\n
\n\t <\/p>\n

\t\tSo sch\u00e4tzen die B\u00f6rsenprofis UBS Aktien ein!<\/a>
\n\t\t\t\t\t\"<b>So<\/p>\n

\t\t\tSeit 2005 liefert der B\u00f6rsenbrief trading-notes verl\u00e4ssliche Anlage-Empfehlungen \u2013 dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
F\u00fcr. Immer. Kostenlos.<\/a> <\/a><\/p>\n

\t
\n\t <\/p>\n


\n\t
\n\t\t\t\t\t\t\tFR0012333284 | UBS | boerse | 69017635 | \t\t\t\t \n\t<\/p>\n


\n <\/p>\n","protected":false},"excerpt":{"rendered":" UBS, Reduces 29.03.2026 – 00:37:34 | boerse-global.de UBS Group reduces its holding in Abivax…\n","protected":false},"author":2,"featured_media":40656,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[23660,23661,1115,23659,8620,16178,23662,2944,19882,223],"class_list":["post-40655","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-abivax","tag-below","tag-biotech","tag-firm","tag-group","tag-reduces","tag-reporting","tag-stake","tag-threshold","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116309628349512874","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/40655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=40655"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/40655\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/40656"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=40655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=40655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=40655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}